Serplulimab with chemotherapy is currently in clinical development as a first-line treatment for extensive-stage small-cell lung cancer (SCLC). SCLC is a very aggressive form of cancer that forms in the tissues of the lungs and often goes undiagnosed until it’s more advanced, so the survival rate tends to be low. Extensive stage SCLC (ES-SCLC) is when the cancer cells spread beyond the lungs to other places in the body. Symptoms include chest discomfort or pain, a cough that does not go away or gets worse, trouble breathing and wheezing. Smoking is the biggest risk factor.ES-SCLC is a challenging disease to treat, and resistance eventually develops relatively quickly in most patients suggesting a clinical need for more effective treatments.
Serplulimab with chemotherapy for treating previously untreated extensive stage small-cell lung cancer
Serplulimab with chemotherapy is currently in clinical development as a first-line treatment for extensive-stage small-cell lung cancer (SCLC). SCLC is a very aggressive form of cancer that forms in the tissues of the lungs and often goes undiagnosed until it’s more advanced, so the survival rate tends to be low.
Interventions:
Serplulimab (HLX10)
Indications:
Small-cell lung cancer (SCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2023